Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.42 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL959417 | 0.86 | MRGPRX4 (0.46) | MRGPRX4ALDH1A1GAAHSD17B14PTGER1 | |
| SCHEMBL957949 | 0.84 | GPR52 (0.44) | MRGPRX4ALDH1A1HPGDL3MBTL1HSD17B14 | |
| SCHEMBL963563 | 0.83 | MRGPRX4 (0.39) | MRGPRX4ALDH1A1POLBHPGDL3MBTL1 | |
| SCHEMBL959429 | 0.82 | MRGPRX4 (0.49) | MRGPRX4ALDH1A1POLBGAAHPGD | |
| SCHEMBL959343 | 0.82 | MRGPRX4 (0.53) | MRGPRX4ALDH1A1POLBGAAHPGD | |
| SCHEMBL958823 | 0.77 | MRGPRX4 (0.49) | MRGPRX4ALDH1A1POLBGAAHPGD | |
| SCHEMBL958590 | 0.77 | MRGPRX4 (0.52) | MRGPRX4ALDH1A1POLBGAAHPGD | |
| SCHEMBL959319 | 0.77 | MRGPRX4 (0.61) | MRGPRX4L3MBTL1PTGER1TTRNPC1 | |
| SCHEMBL957915 | 0.73 | MRGPRX4 (0.50) | MRGPRX4ALDH1A1POLBGAAHPGD | |
| SCHEMBL957846 | 0.73 | MAPT (0.47) | MRGPRX4ALDH1A1POLBGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2253618-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | GPR4, NR3C2, NR5A2 | MRGPRX4 133/4885ALDH1A1 2384/4885POLB 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.